-
公开(公告)号:US08313730B2
公开(公告)日:2012-11-20
申请号:US13285439
申请日:2011-10-31
IPC分类号: A61K49/00 , A61K39/395 , A61K39/40
CPC分类号: C07K16/065 , A61K2039/505 , C07K2317/21 , C07K2317/52
摘要: A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.
-
公开(公告)号:US08119104B2
公开(公告)日:2012-02-21
申请号:US13013648
申请日:2011-01-25
IPC分类号: A61K49/00 , A61K39/395 , A61K39/40
CPC分类号: C07K16/065 , A61K2039/505 , C07K2317/21 , C07K2317/52
摘要: A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.
摘要翻译: 提供了一种用于抑制患有乳糜泻症的受试者症状的方法,其包括施用单克隆抗体或多克隆单体二聚体或聚合物IgA。 将分泌组分连接至IgA限制口服给药降解。 将制剂与单体,二聚体或聚合物IgA混合以产生胶囊,片剂和栓剂的给药形式。 该治疗剂适于直接通过微胶囊包被或剂量形式用肠溶衣包被。
-
公开(公告)号:US20110117143A1
公开(公告)日:2011-05-19
申请号:US13013648
申请日:2011-01-25
申请人: Michael Simon , Mark Andrew Kroenke
发明人: Michael Simon , Mark Andrew Kroenke
IPC分类号: A61K39/395 , A61K9/00 , A61P3/00
CPC分类号: C07K16/065 , A61K2039/505 , C07K2317/21 , C07K2317/52
摘要: A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.
摘要翻译: 提供了一种用于抑制患有乳糜泻症的受试者症状的方法,其包括施用单克隆抗体或多克隆单体二聚体或聚合物IgA。 将分泌组分连接至IgA限制口服给药降解。 将制剂与单体,二聚体或聚合物IgA混合以产生胶囊,片剂和栓剂的给药形式。 该治疗剂适于直接通过微胶囊包被或剂量形式用肠溶衣包被。
-
公开(公告)号:US20120045517A1
公开(公告)日:2012-02-23
申请号:US13285439
申请日:2011-10-31
IPC分类号: A61K39/395 , A61P3/00 , A61K9/50
CPC分类号: C07K16/065 , A61K2039/505 , C07K2317/21 , C07K2317/52
摘要: A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.
摘要翻译: 提供了一种用于抑制患有乳糜泻症的受试者症状的方法,其包括施用单克隆抗体或多克隆单体二聚体或聚合物IgA。 将分泌组分连接至IgA限制口服给药降解。 将制剂与单体,二聚体或聚合物IgA混合以产生胶囊,片剂和栓剂的给药形式。 该治疗剂适于直接通过微胶囊包被或剂量形式用肠溶衣包被。
-
-
-